
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
K202196
B. Purpose for Submission:
To obtain a substantial equivalence determination for the BioFire RP2.1/RP2.1plus Control
Panel M441
C. Measurand:
Multi-analyte quality control materials
D. Type of Test:
BioFire RP2.1/RP2.1plus Control is intended for in vitro diagnostic use as external assayed
quality control materials to monitor the qualitative amplification, detection and identification
steps of the laboratory nucleic acid test, BioFire RP2.1 and RP2.1plus assays on the BioFire
FilmArray Systems, which detects respiratory pathogens: Adenovirus, Coronavirus, Human
Metapneumovirus, Human Rhinovirus/ Enterovirus, Influenza A, Influenza A subtype H1,
Influenza A subtype H1-2009, Influenza A subtype H3, Influenza B, Middle East Respiratory
Syndrome Coronavirus, Parainfluenza Virus, Respiratory Syncytial Virus, Severe Acute
Respiratory Syndrome Coronavirus 2, Bordetella parapertussis, Bordetella pertussis,
Chlamydia pneumoniae, and Mycoplasma pneumoniae
E. Applicant:
Maine Molecular Quality Controls, Inc. (MMQCI)
F. Proprietary and Established Names:
BioFire RP2.1/RP2.1plus Control Panel M441
BioFire RP2.1/RP2.1plus Control
G. Regulatory Information:
1. Regulation section:
21 CFR 866.3920, Assayed quality control material for clinical microbiology assays
2. Classification:
Class II (Special Controls)

--- Page 2 ---
3. Product code:
PMN
4. Panel:
83- Microbiology
H. Indication(s) for use:
1. Indications for use(s):
BioFire RP2.1/RP2.1plus Control Panel M441 is intended for use as an external positive
and negative assayed quality control to monitor the performance of in vitro laboratory
nucleic acid testing procedures for the qualitative detection of Adenovirus, Coronavirus,
Human Metapneumovirus, Human Rhinovirus/ Enterovirus, Influenza A, Influenza A
subtype H1, Influenza A subtype H1-2009, Influenza A subtype H3, Influenza B, Middle
East Respiratory Syndrome Coronavirus, Parainfluenza Virus, Respiratory Syncytial
Virus, Severe Acute Respiratory Syndrome Coronavirus 2, Bordetella parapertussis,
Bordetella pertussis, Chlamydia pneumoniae, and Mycoplasma pneumoniae on the
BioFire Respiratory Panel 2.1 (RP2.1), BioFire Respiratory Panel 2.1 plus (RP2.1plus)
and BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) assays performed on BioFire
FilmArray systems. BioFire RP2.1/RP2.1plus Positive control is composed of synthetic
RNA transcripts specifically designed for and intended to be used solely with the BioFire
RP2.1, BioFire RP2.1plus and BioFire RP2.1-EZ assays. This product is not intended to
replace manufacturer controls provided with the device.
2. Special conditions for use statement(s):
For in vitro diagnostic use only
For prescription use only
3. Special instrument requirements:
The BioFire RP2.1/RP2.1plus Control Panel was evaluated on the FilmArray 2.0
instrument.
I. Device Description:
BioFire RP2.1/RP2.1plus Control Panel M441, P/N M441, is a quality control panel
consisting of 2 ready-to-use, liquid controls, BioFire RP2.1/RP2.1plus Positive (Positive
Control) and BioFire RP2.1/RP2.1plus Negative, (Negative Control). The Positive Control
contains non-infectious surrogate control material; a solution of synthetic RNA transcripts in

--- Page 3 ---
buffer, stabilizers and preservatives. The RNA carries segments of all respiratory pathogens
detected by the BioFire Respiratory Panel 2.1 (RP2.1), BioFire Respiratory Panel 2.1plus
(RP2.1plus), and BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) assays (Table 1. below) on
the BioFire FilmArray systems, including Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2). BioFire RP2.1/RP2.1plus Negative contains buffer and preservatives with
no RNA. Each liquid control of BioFire RP2.1/RP2.1plus.
Control Panel M441 is processed separately according to BioFire RP2.1, RP2.1plus, and
RP2.1-EZ assays manufacturer’s Instructions for Use for patient samples (nasopharyngeal
swabs) obtained from individuals suspected of respiratory tract infection and placed in Viral
Transport Media (VTM)).
Table 1: Pathogens Detected by BioFire RP2.1, RP2.1plus, and RP2.1-EZ assays.
Respiratory Pathogens
Adenovirus Influenza B
Coronavirus 229E Parainfluenza Virus 1
Coronavirus HKU1 Parainfluenza Virus 2
Coronavirus NL63 Parainfluenza Virus 3
Coronavirus OC43 Parainfluenza Virus 4
Middle East Respiratory Syndrome Coronavirus* Respiratory Syncytial Virus
Severe Acute Respiratory Syndrome Coronavirus 2 Bordetella parapertussis (IS001)
Human Metapneumovirus Bordetella pertussis (ptxP)
Human Rhinovirus/ Enterovirus Chlamydia pneumoniae
Influenza A, subtypes H1, H1-2009, H3 Mycoplasma pneumoniae
*Detected by BioFire RP2.1plus assay only.
J. Substantial Equivalence Information:
1. Predicate device name(s):
FilmArray RP2/RP2plus Control Panel, Maine Molecular Quality Controls, Inc.
2. Predicate 510(k) number(s):
K173171
3. Comparison with predicate:
Similarities

[Table 1 on page 3]
	Respiratory Pathogens	
Adenovirus		Influenza B
Coronavirus 229E		Parainfluenza Virus 1
Coronavirus HKU1		Parainfluenza Virus 2
Coronavirus NL63		Parainfluenza Virus 3
Coronavirus OC43		Parainfluenza Virus 4
Middle East Respiratory Syndrome Coronavirus*		Respiratory Syncytial Virus
Severe Acute Respiratory Syndrome Coronavirus 2		Bordetella parapertussis (IS001)
Human Metapneumovirus		Bordetella pertussis (ptxP)
Human Rhinovirus/ Enterovirus		Chlamydia pneumoniae
Influenza A, subtypes H1, H1-2009, H3		Mycoplasma pneumoniae

[Table 2 on page 3]
Similarities


--- Page 4 ---
Similarities
Device: BioFire RP2.1/RP2.1plus Prdeciate: FilmArray
Item Control Pneumonia/Pneumoniaplus
(K202196) Control (K173171)
BioFire RP2.1/RP2.1plus Control Panel FilmArray Pneumonia/Pneumoniaplus
M441 is intended for use as an external Control is intended for use as an external
positive and negative assayed quality positive and negative assayed quality
control to monitor the performance of in control to monitor performance of in vitro
vitro laboratory nucleic acid testing
laboratory nucleic acid testing procedures
procedures for the qualitative detection of
for the qualitative detection of bacteria:
Adenovirus, Coronavirus, Human
Acinetobacter calcoaceticus-baumannii
Metapneumovirus, Human Rhinovirus/
complex, Enterobacter cloacae complex,
Enterovirus, Influenza A, Influenza A
Escherichia coli, Haemophilus influenzae,
subtype H1, Influenza A subtype H1-
Klebsiella aerogenes, Klebsiella oxytoca,
2009, Influenza A subtype H3, Influenza
Klebsiella pneumoniae group, Moraxella
B, Middle East Respiratory Syndrome
catarrhalis, Proteus spp., Pseudomonas
Coronavirus, Parainfluenza Virus,
aeruginosa, Serratia marcescens,
Respiratory Syncytial Virus, Severe Acute
Staphylococcus aureus, Streptococcus
Respiratory Syndrome Coronavirus 2,
Bordetella parapertussis, Bordetella agalactiae, Streptococcus pneumoniae,
pertussis, Chlamydia pneumoniae, and Streptococcus pyogenes, Chlamydia
Mycoplasma pneumoniae on the BioFire pneumoniae, Legionella pneumophila,
Respiratory Panel 2.1 (RP2.1) and BioFire Mycoplasma pneumoniae; antimicrobial
Respiratory Panel 2.1plus (RP2.1plus) resistance genes: CTX-M, IMP, KPC,
Intended Use assays performed on the BioFire mecA/C and MREJ, NDM, OXA-48 like,
FilmArray 2.0 and Torch systems. BioFire VIM; and viruses: Adenovirus,
RP2.1/RP2.1plus Positive control is Coronavirus, Human Metapneumovirus,
composed of synthetic RNA transcripts
Human Rhinovirus/Enterovirus, Influenza
specifically designed for and intended to
A, Influenza B, Middle East Respiratory
be used solely with the BioFire RP2.1
Syndrome Coronavirus (MERS-CoV),
assay and BioFire RP2.1plus assay. This
Parainfluenza Virus and Respiratory
product is not intended to replace
Syncytial Virus on the FilmArray
manufacturer internal controls provided
Pneumonia Panel or Pneumonia Panel
with the device.
plus assays performed on FilmArray
systems. FilmArray
Pneumonia/Pneumoniaplus Control is
composed of synthetic DNA and RNA
specifically designed for and intended to
be used solely with the FilmArray
Pneumonia Panel and FilmArray
Pneumonia Panel plus assays. This
product is not intended to replace
manufacturer controls provided with the
device.
Physical Format Same Ready-to-Use Liquid
Directions for
Same Process like patient sample
Use
Reverse transcription,
Assay Steps
Same amplification, detection,
Monitored
identification

[Table 1 on page 4]
Similarities		
		
	Device: BioFire RP2.1/RP2.1plus	Prdeciate: FilmArray
Item	Control	Pneumonia/Pneumoniaplus
	(K202196)	Control (K173171)
Intended Use	BioFire RP2.1/RP2.1plus Control Panel
M441 is intended for use as an external
positive and negative assayed quality
control to monitor the performance of in
vitro laboratory nucleic acid testing
procedures for the qualitative detection of
Adenovirus, Coronavirus, Human
Metapneumovirus, Human Rhinovirus/
Enterovirus, Influenza A, Influenza A
subtype H1, Influenza A subtype H1-
2009, Influenza A subtype H3, Influenza
B, Middle East Respiratory Syndrome
Coronavirus, Parainfluenza Virus,
Respiratory Syncytial Virus, Severe Acute
Respiratory Syndrome Coronavirus 2,
Bordetella parapertussis, Bordetella
pertussis, Chlamydia pneumoniae, and
Mycoplasma pneumoniae on the BioFire
Respiratory Panel 2.1 (RP2.1) and BioFire
Respiratory Panel 2.1plus (RP2.1plus)
assays performed on the BioFire
FilmArray 2.0 and Torch systems. BioFire
RP2.1/RP2.1plus Positive control is
composed of synthetic RNA transcripts
specifically designed for and intended to
be used solely with the BioFire RP2.1
assay and BioFire RP2.1plus assay. This
product is not intended to replace
manufacturer internal controls provided
with the device.	FilmArray Pneumonia/Pneumoniaplus
Control is intended for use as an external
positive and negative assayed quality
control to monitor performance of in vitro
laboratory nucleic acid testing procedures
for the qualitative detection of bacteria:
Acinetobacter calcoaceticus-baumannii
complex, Enterobacter cloacae complex,
Escherichia coli, Haemophilus influenzae,
Klebsiella aerogenes, Klebsiella oxytoca,
Klebsiella pneumoniae group, Moraxella
catarrhalis, Proteus spp., Pseudomonas
aeruginosa, Serratia marcescens,
Staphylococcus aureus, Streptococcus
agalactiae, Streptococcus pneumoniae,
Streptococcus pyogenes, Chlamydia
pneumoniae, Legionella pneumophila,
Mycoplasma pneumoniae; antimicrobial
resistance genes: CTX-M, IMP, KPC,
mecA/C and MREJ, NDM, OXA-48 like,
VIM; and viruses: Adenovirus,
Coronavirus, Human Metapneumovirus,
Human Rhinovirus/Enterovirus, Influenza
A, Influenza B, Middle East Respiratory
Syndrome Coronavirus (MERS-CoV),
Parainfluenza Virus and Respiratory
Syncytial Virus on the FilmArray
Pneumonia Panel or Pneumonia Panel
plus assays performed on FilmArray
systems. FilmArray
Pneumonia/Pneumoniaplus Control is
composed of synthetic DNA and RNA
specifically designed for and intended to
be used solely with the FilmArray
Pneumonia Panel and FilmArray
Pneumonia Panel plus assays. This
product is not intended to replace
manufacturer controls provided with the
device.
Physical Format	Same	Ready-to-Use Liquid
Directions for
Use	Same	Process like patient sample
Assay Steps
Monitored	Same	Reverse transcription,
amplification, detection,
identification

--- Page 5 ---
Similarities
Number of
Same Multiple
Targets
Composition Same Synthetic RNA & DNA transcripts
Differences
Device: BioFire RP2.1/RP2.1plus Prdeciate: FilmArray
Item Control Pneumonia/Pneumoniaplus
(K202196) Control (K173171)
Adenovirus, Coronavirus, Human Acinetobacter calcoaceticus-baumannii
Metapneumovirus, Human Rhinovirus/ complex, Enterobacter cloacae complex,
Enterovirus, Influenza A, Influenza A Escherichia coli, Haemophilus influenzae,
subtype H1, Influenza A subtype H1- Klebsiella aerogenes, Klebsiella oxytoca,
2009, Influenza A subtype H3, Influenza Klebsiella pneumoniae group, Moraxella
B, Middle East Respiratory Syndrome catarrhalis, Proteus spp., Pseudomonas
Coronavirus, Parainfluenza Virus, aeruginosa, Serratia marcescens,
Respiratory Syncytial Virus, Severe Acute Staphylococcus aureus, Streptococcus
Respiratory Syndrome Coronavirus 2, agalactiae, Streptococcus pneumoniae,
Bordetella parapertussis, Bordetella Streptococcus pyogenes, Chlamydia
Targets pertussis, Chlamydia pneumoniae, and pneumoniae, Legionella pneumophila,
Mycoplasma pneumoniae Mycoplasma pneumoniae; antimicrobial
resistance genes: CTX-M, IMP, KPC,
mecA/C and MREJ, NDM, OXA-48 like,
VIM; and viruses: Adenovirus,
Coronavirus, Human Metapneumovirus,
Human Rhinovirus/Enterovirus, Influenza
A, Influenza B, Middle East Respiratory
Syndrome Coronavirus (MERS-CoV),
Parainfluenza Virus and Respiratory
Syncytial Virus
K. Standard/Guidance Document Referenced (if applicable):
None were referenced
L. Test Principle:
Not applicable
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. External Site Precision:

[Table 1 on page 5]
Similarities		
		
Number of
Targets	Same	Multiple
Composition	Same	Synthetic RNA & DNA transcripts

[Table 2 on page 5]
Differences		
		
	Device: BioFire RP2.1/RP2.1plus	Prdeciate: FilmArray
Item	Control	Pneumonia/Pneumoniaplus
	(K202196)	Control (K173171)
Targets	Adenovirus, Coronavirus, Human
Metapneumovirus, Human Rhinovirus/
Enterovirus, Influenza A, Influenza A
subtype H1, Influenza A subtype H1-
2009, Influenza A subtype H3, Influenza
B, Middle East Respiratory Syndrome
Coronavirus, Parainfluenza Virus,
Respiratory Syncytial Virus, Severe Acute
Respiratory Syndrome Coronavirus 2,
Bordetella parapertussis, Bordetella
pertussis, Chlamydia pneumoniae, and
Mycoplasma pneumoniae	Acinetobacter calcoaceticus-baumannii
complex, Enterobacter cloacae complex,
Escherichia coli, Haemophilus influenzae,
Klebsiella aerogenes, Klebsiella oxytoca,
Klebsiella pneumoniae group, Moraxella
catarrhalis, Proteus spp., Pseudomonas
aeruginosa, Serratia marcescens,
Staphylococcus aureus, Streptococcus
agalactiae, Streptococcus pneumoniae,
Streptococcus pyogenes, Chlamydia
pneumoniae, Legionella pneumophila,
Mycoplasma pneumoniae; antimicrobial
resistance genes: CTX-M, IMP, KPC,
mecA/C and MREJ, NDM, OXA-48 like,
VIM; and viruses: Adenovirus,
Coronavirus, Human Metapneumovirus,
Human Rhinovirus/Enterovirus, Influenza
A, Influenza B, Middle East Respiratory
Syndrome Coronavirus (MERS-CoV),
Parainfluenza Virus and Respiratory
Syncytial Virus

--- Page 6 ---
An external site precision study was performed with the BioFire RP2.1/RP2.1plus
Control Panel on FilmArray instrument 2.0 and FilmArray Torch systems. Multiple
operators participated using three lots each of external control material and three lots
of BioFire RP2.1 assays pouch lots were tested across all sites. A total of 52 external
controls were tested (27 positive and 25 negative). The results are shown in the
Tables 2 below:
Table 2: BioFire RP2.1/RP2.1plus Control Panel External Precision Study Summary
%
#expected
Agreement with Overall Percent 95% Confidence
Category results/#
Expected Result Agreement Interval
tested1
1
BioFire
100%
RP2.1/RP2.1plus 26/27* 100% 87.1% to 100%%
26/26
Positive Control
BioFire
100%
RP2.1/RP2.1plus 25/25 100% 86.7% to 100%
25/25
Negative Control
* 1 Invalid sample was not included in the Percent Correct analysis.
Table 3: External Precision Crossing Point (Cp) Summary
Lot #1 Lot #2 Lot #3 All Lot #’s
Analyte Ave Cp SD Ave Cp SD Ave Cp SD Ave Cp SD %CV
Adeno2 18.6 3.1 18.0 0.7 18.1 1.6 18.3 2.1 11.6%
Adeno3 18.4 1.4 17.5 1.7 19.2 1.6 18.4 1.6 8.9%
Adeno6 16.1 1.0 15.4 1.3 16.7 1.1 16.1 1.2 7.5%
Adeno7.1 15.2 0.6 15.2 0.8 15.2 0.6 15.2 0.6 4.3%
Adeno8 13.7 0.4 13.7 0.7 14.1 0.5 13.8 0.5 3.8%
CoV-229E 15.8 0.5 15.9 0.4 15.8 0.5 15.8 0.4 2.7%
CoV-HKU1 17.2 0.4 17.3 0.5 17.3 0.5 17.3 0.5 2.6%
CoV-NL63 16.0 0.5 16.1 0.5 16.1 0.6 16.1 0.5 3.1%
CoV-OC43-2 17.2 0.7 17.3 0.5 17.1 0.8 17.2 0.7 3.8%
MERS1 17.0 0.7 16.9 0.5 16.9 0.5 16.9 0.6 3.3%
MERS2 16.2 0.7 16.2 0.6 16.3 0.7 16.3 0.6 4.0%
SARSCoV2-1 12.4 0.3 12.4 0.4 12.2 0.3 12.4 0.4 2.9%
SARSCoV2-2 15.5 0.4 15.3 0.7 15.3 0.4 15.4 0.5 3.3%
hMPV 14.5 0.7 14.3 0.8 14.3 0.7 14.4 0.7 4.8%
HRV/EV 16.2 0.4 16.3 0.4 16.4 0.6 16.3 0.5 3.0%
FluA-H1-2 18.4 0.5 18.2 0.7 18.3 0.7 18.3 0.6 3.3%
FluA-H1-2009 17.8 0.5 17.8 0.5 17.8 0.5 17.8 0.5 2.7%
FluA-H3 15.3 0.5 15.5 0.4 15.4 0.5 15.4 0.4 2.8%
FluA-pan1 15.3 0.4 15.5 0.5 15.4 0.6 15.4 0.5 3.0%
FluA-pan2 16.1 0.4 16.2 0.5 16.0 0.7 16.1 0.5 3.2%

[Table 1 on page 6]
Category	#expected
results/#
tested1	A
E	%	h
t	Overall Percent
Agreement	95% Confidence
Interval
			greement wit			
			xpected Resul			
			1			
BioFire
RP2.1/RP2.1plus
Positive Control	26/27*	100%			100%
26/26	87.1% to 100%%
BioFire
RP2.1/RP2.1plus
Negative Control	25/25	100%			100%
25/25	86.7% to 100%

[Table 2 on page 6]
#expected
results/#
tested1

[Table 3 on page 6]
Overall Percent
Agreement

[Table 4 on page 6]
95% Confidence
Interval

[Table 5 on page 6]
	Lot #1		Lot #2		Lot #3		All Lot #’s		
Analyte									
	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	%CV
Adeno2	18.6	3.1	18.0	0.7	18.1	1.6	18.3	2.1	11.6%
Adeno3	18.4	1.4	17.5	1.7	19.2	1.6	18.4	1.6	8.9%
Adeno6	16.1	1.0	15.4	1.3	16.7	1.1	16.1	1.2	7.5%
Adeno7.1	15.2	0.6	15.2	0.8	15.2	0.6	15.2	0.6	4.3%
Adeno8	13.7	0.4	13.7	0.7	14.1	0.5	13.8	0.5	3.8%
CoV-229E	15.8	0.5	15.9	0.4	15.8	0.5	15.8	0.4	2.7%
CoV-HKU1	17.2	0.4	17.3	0.5	17.3	0.5	17.3	0.5	2.6%
CoV-NL63	16.0	0.5	16.1	0.5	16.1	0.6	16.1	0.5	3.1%
CoV-OC43-2	17.2	0.7	17.3	0.5	17.1	0.8	17.2	0.7	3.8%
MERS1	17.0	0.7	16.9	0.5	16.9	0.5	16.9	0.6	3.3%
MERS2	16.2	0.7	16.2	0.6	16.3	0.7	16.3	0.6	4.0%
SARSCoV2-1	12.4	0.3	12.4	0.4	12.2	0.3	12.4	0.4	2.9%
SARSCoV2-2	15.5	0.4	15.3	0.7	15.3	0.4	15.4	0.5	3.3%
hMPV	14.5	0.7	14.3	0.8	14.3	0.7	14.4	0.7	4.8%
HRV/EV	16.2	0.4	16.3	0.4	16.4	0.6	16.3	0.5	3.0%
FluA-H1-2	18.4	0.5	18.2	0.7	18.3	0.7	18.3	0.6	3.3%
FluA-H1-2009	17.8	0.5	17.8	0.5	17.8	0.5	17.8	0.5	2.7%
FluA-H3	15.3	0.5	15.5	0.4	15.4	0.5	15.4	0.4	2.8%
FluA-pan1	15.3	0.4	15.5	0.5	15.4	0.6	15.4	0.5	3.0%
FluA-pan2	16.1	0.4	16.2	0.5	16.0	0.7	16.1	0.5	3.2%

--- Page 7 ---
Lot #1 Lot #2 Lot #3 All Lot #’s
Analyte Ave Cp SD Ave Cp SD Ave Cp SD Ave Cp SD %CV
FluB 14.8 0.4 15.2 0.5 15.1 0.4 15.0 0.4 2.9%
PIV1 14.0 0.6 13.8 0.6 13.9 0.8 13.9 0.6 4.4%
PIV2 17.4 0.4 17.5 0.5 17.4 0.5 17.4 0.4 2.5%
PIV3 17.1 0.4 17.3 0.3 17.2 0.5 17.2 0.4 2.2%
PIV4 17.3 0.5 17.5 0.6 17.4 0.5 17.4 0.5 2.8%
RSV 14.8 0.2 15.1 0.4 15.0 0.5 14.9 0.4 2.6%
IS1001 17.7 0.8 17.9 0.7 18.6 1.1 18.0 0.9 5.2%
ptxP 15.4 1.1 15.0 1.1 16.0 1.2 15.5 1.2 7.5%
Cpne 15.2 0.5 15.4 0.5 15.3 0.5 15.3 0.5 3.0%
Mpne 15.5 0.3 15.6 0.4 15.4 0.5 15.5 0.4 2.5%
The results suggest that there are no significant differences between different users
and different lots on different days. The external precision study for the BioFire
RP2.1/RP2.1plus Control Panel are is acceptable.
b. Internal Precision:
An internal precision study for the BioFire RP2.1/RP2.1plus Control Panel was
conducted over twenty days by testing three BioFire RP2.1/RP2.1plus Control Panel
lots with three BioFire RP2.1 assay lots performed by three operators using two
FilmArray 2.0 instruments. The results are shown in the Table 4 below:
Table 4: BioFire RP2.1/RP2.1plus Control Panel Internal Precision Summary
#expected results/ Overall Percent
Category 95% Confidence Interval
#tested1 Agreement
BioFire
RP2.1/RP2.1plus 60/60 100% 94% to 100%
Negative Control
BioFire
RP2.1/RP2.1plus 60/60 100% 94% to 100%
Positive Control
Table 5: Precision Internal Crossing Point (Cp) Summary
D24APR20A F28APR20A C29APR20A All Lots
Analyte
Ave Cp SD Ave Cp SD Ave Cp SD Ave Cp SD %CV
Adeno2 17.8 1.5 18.5 1.6 17.9 2.1 18.1 1.8 9.7%
Adeno3 18.1 1.5 18.3 1.5 17.8 1.7 18.1 1.6 8.7%
Adeno6 15.9 1.4 15.9 1.4 15.7 1.4 15.8 1.4 8.7%
Adeno7.1 16.1 1.8 16.1 1.2 15.7 1.3 16.0 1.4 9.0%
Adeno8 14.2 1.3 14.3 1.0 14.0 1.0 14.2 1.1 7.5%

[Table 1 on page 7]
	Lot #1		Lot #2		Lot #3		All Lot #’s		
Analyte									
	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	%CV
FluB	14.8	0.4	15.2	0.5	15.1	0.4	15.0	0.4	2.9%
PIV1	14.0	0.6	13.8	0.6	13.9	0.8	13.9	0.6	4.4%
PIV2	17.4	0.4	17.5	0.5	17.4	0.5	17.4	0.4	2.5%
PIV3	17.1	0.4	17.3	0.3	17.2	0.5	17.2	0.4	2.2%
PIV4	17.3	0.5	17.5	0.6	17.4	0.5	17.4	0.5	2.8%
RSV	14.8	0.2	15.1	0.4	15.0	0.5	14.9	0.4	2.6%
IS1001	17.7	0.8	17.9	0.7	18.6	1.1	18.0	0.9	5.2%
ptxP	15.4	1.1	15.0	1.1	16.0	1.2	15.5	1.2	7.5%
Cpne	15.2	0.5	15.4	0.5	15.3	0.5	15.3	0.5	3.0%
Mpne	15.5	0.3	15.6	0.4	15.4	0.5	15.5	0.4	2.5%

[Table 2 on page 7]
Category		#expected results/
#tested1		Overall Percent		95% Confidence Interval
				Agreement		
BioFire
RP2.1/RP2.1plus
Negative Control	60/60		100%			94% to 100%
BioFire
RP2.1/RP2.1plus
Positive Control	60/60		100%			94% to 100%

[Table 3 on page 7]
									
	D24APR20A		F28APR20A		C29APR20A		All Lots		
Analyte									
									
									
	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	%CV
Adeno2	17.8	1.5	18.5	1.6	17.9	2.1	18.1	1.8	9.7%
Adeno3	18.1	1.5	18.3	1.5	17.8	1.7	18.1	1.6	8.7%
Adeno6	15.9	1.4	15.9	1.4	15.7	1.4	15.8	1.4	8.7%
Adeno7.1	16.1	1.8	16.1	1.2	15.7	1.3	16.0	1.4	9.0%
Adeno8	14.2	1.3	14.3	1.0	14.0	1.0	14.2	1.1	7.5%

--- Page 8 ---
D24APR20A F28APR20A C29APR20A All Lots
Analyte
CoV-229E 16.3 0.8 16.8 0.7 16.2 0.7 16.4 0.8 4.7%
CoV-HKU1 17.7 1.2 17.9 0.7 17.6 0.8 17.7 0.9 5.1%
CoV-NL63 17.2 1.2 17.3 0.7 17.1 0.9 17.2 0.9 5.4%
CoV-OC43-2 18.3 1.7 18.4 0.9 18.3 1.3 18.3 1.3 7.2%
MERS1 17.9 1.8 18.0 0.8 17.9 1.4 17.9 1.4 7.6%
MERS2 16.9 1.2 17.2 0.7 16.9 1.1 17.0 1.0 5.9%
SARSCoV2-1 13.2 0.8 13.4 0.5 12.9 0.6 13.2 0.7 5.2%
SARSCoV2-2 16.4 1.3 16.3 0.6 16.0 0.9 16.2 1.0 5.9%
hMPV 15.4 1.7 15.3 1.1 14.9 1.2 15.2 1.4 9.1%
HRV/EV 16.8 1.0 17.2 0.7 16.7 0.8 16.9 0.9 5.1%
FluA-H1-2 19.1 1.4 19.4 1.0 18.9 1.1 19.1 1.2 6.2%
FluA-H1-2009 18.4 1.5 18.5 0.9 18.3 1.1 18.4 1.2 6.4%
FluA-H3 15.9 0.8 16.4 0.5 16.0 0.7 16.1 0.7 4.2%
FluA-pan1 15.7 0.7 16.1 0.5 15.6 0.6 15.8 0.7 4.2%
FluA-pan2 16.8 1.1 17.1 0.9 16.6 0.8 16.8 0.9 5.6%
FluB 15.4 0.7 15.9 0.4 15.5 0.5 15.6 0.6 3.8%
PIV1 15.0 1.6 15.0 1.1 14.8 1.2 14.9 1.3 8.9%
PIV2 18.1 1.3 18.3 0.8 17.9 0.9 18.1 1.0 5.5%
PIV3 17.7 1.2 18.0 0.8 17.6 0.8 17.8 1.0 5.4%
PIV4 17.9 1.2 18.4 0.8 17.9 0.9 18.1 1.0 5.5%
RSV 15.4 0.8 15.8 0.5 15.5 0.5 15.6 0.6 4.1%
IS1001 18.1 1.0 18.6 1.0 18.2 1.1 18.3 1.0 5.7%
ptxP 15.3 1.3 15.7 1.2 15.2 1.3 15.4 1.3 8.2%
Cpne 15.7 0.8 16.2 0.6 15.6 0.6 15.8 0.7 4.5%
Mpne 16.2 1.2 16.4 0.7 16.0 0.8 16.2 0.9 5.8%
There appears to be no significant differences in mean Cp value when testing different
control lots on different days. Precision studies are acceptable.
c. Lot-to-Lot Testing:
Lot-to-lot reproducibility was demonstrated by testing three lots of BioFire
RP2.1/RP2.1plus Positive using the same pouch lot. Results are shown in the
following tables.
Table 6: BioFire RP2.1/RP2.1plus Positive Panel Summary of Lot-to-Lot Reproducibility
Control Lot # Number of Tests Pouch Lot Correct Results
D24APR20 5 200409 5/5
F28APR20 5 200409 5/5
C29APR20 5 200409 5/5
Table 7: Lot to Lot Internal Crossing Point (Cp) Summary

[Table 1 on page 8]
									
	D24APR20A		F28APR20A		C29APR20A		All Lots		
Analyte									
									
									
CoV-229E	16.3	0.8	16.8	0.7	16.2	0.7	16.4	0.8	4.7%
CoV-HKU1	17.7	1.2	17.9	0.7	17.6	0.8	17.7	0.9	5.1%
CoV-NL63	17.2	1.2	17.3	0.7	17.1	0.9	17.2	0.9	5.4%
CoV-OC43-2	18.3	1.7	18.4	0.9	18.3	1.3	18.3	1.3	7.2%
MERS1	17.9	1.8	18.0	0.8	17.9	1.4	17.9	1.4	7.6%
MERS2	16.9	1.2	17.2	0.7	16.9	1.1	17.0	1.0	5.9%
SARSCoV2-1	13.2	0.8	13.4	0.5	12.9	0.6	13.2	0.7	5.2%
SARSCoV2-2	16.4	1.3	16.3	0.6	16.0	0.9	16.2	1.0	5.9%
hMPV	15.4	1.7	15.3	1.1	14.9	1.2	15.2	1.4	9.1%
HRV/EV	16.8	1.0	17.2	0.7	16.7	0.8	16.9	0.9	5.1%
FluA-H1-2	19.1	1.4	19.4	1.0	18.9	1.1	19.1	1.2	6.2%
FluA-H1-2009	18.4	1.5	18.5	0.9	18.3	1.1	18.4	1.2	6.4%
FluA-H3	15.9	0.8	16.4	0.5	16.0	0.7	16.1	0.7	4.2%
FluA-pan1	15.7	0.7	16.1	0.5	15.6	0.6	15.8	0.7	4.2%
FluA-pan2	16.8	1.1	17.1	0.9	16.6	0.8	16.8	0.9	5.6%
FluB	15.4	0.7	15.9	0.4	15.5	0.5	15.6	0.6	3.8%
PIV1	15.0	1.6	15.0	1.1	14.8	1.2	14.9	1.3	8.9%
PIV2	18.1	1.3	18.3	0.8	17.9	0.9	18.1	1.0	5.5%
PIV3	17.7	1.2	18.0	0.8	17.6	0.8	17.8	1.0	5.4%
PIV4	17.9	1.2	18.4	0.8	17.9	0.9	18.1	1.0	5.5%
RSV	15.4	0.8	15.8	0.5	15.5	0.5	15.6	0.6	4.1%
IS1001	18.1	1.0	18.6	1.0	18.2	1.1	18.3	1.0	5.7%
ptxP	15.3	1.3	15.7	1.2	15.2	1.3	15.4	1.3	8.2%
Cpne	15.7	0.8	16.2	0.6	15.6	0.6	15.8	0.7	4.5%
Mpne	16.2	1.2	16.4	0.7	16.0	0.8	16.2	0.9	5.8%

[Table 2 on page 8]
			
Control Lot #	Number of Tests	Pouch Lot	Correct Results
			
D24APR20	5	200409	5/5
F28APR20	5	200409	5/5
C29APR20	5	200409	5/5

--- Page 9 ---
D24APR20 F28APR20 C29APR20 All lots All Lots
Analyte
Mean Cp Mean Cp Mean Cp Mean SD
Cp
Adeno2 18.9 18.9 19.0 18.9 0.1
Adeno3 19.3 19.8 19.4 19.5 0.3
Adeno6 16.8 17.2 16.7 16.9 0.2
Adeno7.1 16.6 16.9 16.5 16.7 0.2
Adeno8 14.6 14.9 14.6 14.7 0.2
CoV-229E 16.8 16.9 16.8 16.8 0.1
CoV-HKU1 18.1 18.1 18.1 18.1 0.0
CoV-NL63 17.8 17.9 17.7 17.8 0.1
CoV-OC43-2 18.9 19.1 18.7 18.9 0.2
MERS1 18.9 18.8 18.8 18.8 0.1
MERS2 17.6 17.6 17.6 17.6 0.0
SARSCoV2-1 13.7 13.5 13.7 13.7 0.1
SARSCoV2-2 16.8 16.7 16.8 16.8 0.1
hMPV 16.0 15.9 15.9 15.9 0.1
HRV/EV 17.4 17.5 17.4 17.4 0.1
FluA-H1-2 19.7 20.0 19.6 19.7 0.2
FluA-H1-2009 18.9 18.9 18.8 18.8 0.1
FluA-H3 16.4 16.5 16.4 16.4 0.1
FluA-pan1 16.1 16.2 16.1 16.1 0.1
FluA-pan2 17.3 17.4 17.3 17.3 0.1
FluB 15.7 15.9 15.8 15.8 0.1
PIV1 15.7 15.7 15.6 15.6 0.1
PIV2 18.6 18.7 18.5 18.6 0.1
PIV3 18.0 18.2 18.0 18.1 0.1
PIV4 18.4 18.5 18.3 18.4 0.1
RSV 15.8 15.9 15.7 15.8 0.1
IS1001 18.9 19.3 18.9 19.0 0.3
ptxP 16.1 16.5 16.1 16.3 0.2
Cpne 16.1 16.2 16.1 16.2 0.1
Mpne 16.8 16.7 16.6 16.7 0.1
Lot-to-Lot reproducibility studies for the BioFire RP2.1/RP2.1plus Positive Panel are
acceptable.
e. Linearity/assay reportable range:
Not applicable
f. Traceability, Stability, Expected values (controls, calibrators, or methods):

[Table 1 on page 9]
Analyte	D24APR20	F28APR20	C29APR20	All lots	All Lots
	Mean Cp	Mean Cp	Mean Cp	Mean	SD
					
				Cp	
Adeno2	18.9	18.9	19.0	18.9	0.1
Adeno3	19.3	19.8	19.4	19.5	0.3
Adeno6	16.8	17.2	16.7	16.9	0.2
Adeno7.1	16.6	16.9	16.5	16.7	0.2
Adeno8	14.6	14.9	14.6	14.7	0.2
CoV-229E	16.8	16.9	16.8	16.8	0.1
CoV-HKU1	18.1	18.1	18.1	18.1	0.0
CoV-NL63	17.8	17.9	17.7	17.8	0.1
CoV-OC43-2	18.9	19.1	18.7	18.9	0.2
MERS1	18.9	18.8	18.8	18.8	0.1
MERS2	17.6	17.6	17.6	17.6	0.0
SARSCoV2-1	13.7	13.5	13.7	13.7	0.1
SARSCoV2-2	16.8	16.7	16.8	16.8	0.1
hMPV	16.0	15.9	15.9	15.9	0.1
HRV/EV	17.4	17.5	17.4	17.4	0.1
FluA-H1-2	19.7	20.0	19.6	19.7	0.2
FluA-H1-2009	18.9	18.9	18.8	18.8	0.1
FluA-H3	16.4	16.5	16.4	16.4	0.1
FluA-pan1	16.1	16.2	16.1	16.1	0.1
FluA-pan2	17.3	17.4	17.3	17.3	0.1
FluB	15.7	15.9	15.8	15.8	0.1
PIV1	15.7	15.7	15.6	15.6	0.1
PIV2	18.6	18.7	18.5	18.6	0.1
PIV3	18.0	18.2	18.0	18.1	0.1
PIV4	18.4	18.5	18.3	18.4	0.1
RSV	15.8	15.9	15.7	15.8	0.1
IS1001	18.9	19.3	18.9	19.0	0.3
ptxP	16.1	16.5	16.1	16.3	0.2
Cpne	16.1	16.2	16.1	16.2	0.1
Mpne	16.8	16.7	16.6	16.7	0.1

--- Page 10 ---
Traceability:
Not applicable
Stability:
Open Vial Stability: Not applicable because BioFire RP2.1/RP2.1plus Panel Control
is packaged for single use.
Closed Vial Real-time Stability: An accelerated stability study was performed to
establish the shelf life stability claims for BioFire RP2.1/RP2.1plus Panel Control.
Based on this study, the BioFire RP2.1/RP2.1plus Panel Control is expected to be
stable until the expiration date (24 months) when stored frozen (–20°C or colder) and
unopened. This product is for single use.
Real-Time Stability Program: Real-time stability studies are ongoing to support
product claims and to monitor potential assay modifications for which the BioFire
RP2.1/RP2.1plus Panel Control is indicated for use. Real-time stability study
protocols and acceptance criteria were reviewed and found to be acceptable.
Shipping Stability: MMQCI ships the BioFire RP2.1/RP2.1plus Panel Control on dry
ice with overnight delivery, ensuring that the control material remains frozen upon
receipt. The frozen control material is then to be stored at -20oC, as indicated in the
BioFire RP2.1/RP2.1plus Panel Control package insert. A shipping study was
performed to confirm the shipping process and to investigate the outcome of a
possible shipping delay and subsequent arrival with no dry ice. The study evaluated
two lots of the BioFire RP2.1/RP2.1plus Positive control that was placed in dry ice
that was stored for two days at ambient temperature of approximately 19-21°C and
then tested using the FilmArray Pneumonia/Pneumonia plus assay. To simulate a
shipping delay, additional samples of the two lots of the Positive Control that had
been stored in dry ice, were removed from the dry ice and placed at ambient
temperature for six days. The ‘delayed’ samples were tested at two and six days of
ambient temperature with the BioFire RP2plus assay.
The study demonstrated that the BioFire RP2.1/RP2.1plus Positive Control is stable
for two days on dry ice in MMQCI’s standard shipping box. BioFire
RP2.1/RP2.1plus Positive Control is stable after six days at ambient temperatures of
approximately 19-21°C. The FilmArray Pneumonia/Pneumoniaplus Positive Control
should be stored frozen (–20°C or colder) as indicated in the package insert.
Expected Values:
BioFire RP2.1/RP2.1plus Panel Control is a qualitative control and the expected
results are listed in the tables below.
Table 10: BioFire RP2.1/RP2.1plus Positive & Negative Result Summary
Result Summary

--- Page 11 ---
Result Summary
Positive Negative
Viruses
Adenovirus Detected Not Detected
Coronavirus 229E Detected Not Detected
Coronavirus HKU1 Detected Not Detected
Coronavirus NL63 Detected Not Detected
Coronavirus OC43 Detected Not Detected
Middle East Respiratory
Syndrome Coronavirus* Detected Not Detected
(MERS-CoV)2
Severe Acute Respiratory
Syndrome Coronavirus 2 Detected Not Detected
(SARS-CoV-2)
Human Metapneumovirus Detected Not Detected
Human Rhinovirus/
Detected Not Detected
Enterovirus
Influenza A H1-20091 Detected Not Detected
Influenza A H3 Detected Not Detected
Influenza B Detected Not Detected
Parainfluenza Virus 1 Detected Not Detected
Parainfluneza Virus 2 Detected Not Detected
Parainfluenza Virus 3 Detected Not Detected
Parainfluenza Virus 4 Detected Not Detected
Respiratory Syncytial Virus Detected Not Detected
Bacteria
Bordetella parapertussis
Detected Not Detected
(IS1001)
Bordetella pertussis (ptxP) Detected Not Detected
Chlamydia pneumoniae Detected Not Detected
Mycoplasma pneumoniae Detected Not Detected
1 BioFire RP2.1/RP2.1plus Positive contains both Influenza A H1 and Influenza A H1-2009.
Due to BioFire FilmArray 2.0 Software calling algorithm, only Influenza A H1-2009 will
report as Detected, just as if a co-infection of Influenza A H1-2009 and another Influenza A
H1 has occurred. To confirm successful detection of Influenza A H1, view the melt curve by
following BioFire’s Technical Note: Torch Melting Curve Analysis with FilmArray 2.0
Software. For questions related to software, please contact BioFire Technical Support.
2 Middle East Respiratory Syndrome Coronavirus is reported on RP2.1plus assay only.
Matrix Effects:
A study was performed to evaluate the effect of the BioFire RP2.1/RP2.1plus Panel
Control in the presence of VTM matrix. A VTM sample positive for Influenza A
H1N1-2009 was spiked into a negative VTM and into a RP2/RP2plus Negative
Control matrix and tested in triplicate by the FilmArray Pneumonia/Pneumonia plus
assay. No inhibition and/or false negative results were observed with either the spiked
sample in VTM or the RP2/RP2plus Negative Control matrix.

[Table 1 on page 11]
Result Summary		
	Positive	Negative
		
Viruses		
		
Adenovirus	Detected	Not Detected
Coronavirus 229E	Detected	Not Detected
Coronavirus HKU1	Detected	Not Detected
Coronavirus NL63	Detected	Not Detected
Coronavirus OC43	Detected	Not Detected
Middle East Respiratory
Syndrome Coronavirus*
(MERS-CoV)2	Detected	Not Detected
Severe Acute Respiratory
Syndrome Coronavirus 2
(SARS-CoV-2)	Detected	Not Detected
Human Metapneumovirus	Detected	Not Detected
Human Rhinovirus/
Enterovirus	Detected	Not Detected
Influenza A H1-20091	Detected	Not Detected
Influenza A H3	Detected	Not Detected
Influenza B	Detected	Not Detected
Parainfluenza Virus 1	Detected	Not Detected
Parainfluneza Virus 2	Detected	Not Detected
Parainfluenza Virus 3	Detected	Not Detected
Parainfluenza Virus 4	Detected	Not Detected
Respiratory Syncytial Virus	Detected	Not Detected
Bacteria		
Bordetella parapertussis
(IS1001)	Detected	Not Detected
Bordetella pertussis (ptxP)	Detected	Not Detected
Chlamydia pneumoniae	Detected	Not Detected
Mycoplasma pneumoniae	Detected	Not Detected

--- Page 12 ---
Results demonstrated that samples prepared with VTM matrix showed no inhibition
and/or false negative results were observed with either the spiked sample or with the
BioFire RP2/RP2plus Negative control matrix.
g. Detection limit:
Not applicable
h. Analytical Reactivity (Inclusivity):
Not applicable
i. Cross Reactivity:
Not applicable
j. Interference:
Not applicable
k. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
Not applicable.
3. Clinical Studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not Applicable.

--- Page 13 ---
N. Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.